Diffusion Pharmaceuticals (NASDAQ:DFFN) – Stock analysts at Zacks Investment Research issued their Q2 2018 EPS estimates for shares of Diffusion Pharmaceuticals in a report released on Thursday, April 19th. Zacks Investment Research analyst D. Bautz anticipates that the company will earn ($0.06) per share for the quarter. Zacks Investment Research also issued estimates for Diffusion Pharmaceuticals’ Q4 2018 earnings at ($0.07) EPS.
Separately, HC Wainwright assumed coverage on shares of Diffusion Pharmaceuticals in a research note on Wednesday, March 21st. They set a “buy” rating and a $1.25 target price for the company.
Shares of DFFN opened at $0.54 on Monday. Diffusion Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $3.93.
ILLEGAL ACTIVITY WARNING: “Brokers Issue Forecasts for Diffusion Pharmaceuticals’ Q2 2018 Earnings (DFFN)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/25/brokers-issue-forecasts-for-diffusion-pharmaceuticals-q2-2018-earnings-dffn.html.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. Its lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer.
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.